Alpha 2.0
Login Register
» Authors » Hitoshi Ishizuka

Hitoshi Ishizuka

Explore the profile of Hitoshi Ishizuka including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 37
Citations 194
Followers 0
Related Specialties
Pharmacology
Biochemistry
General Medicine
Top 10 Co-Authors
Kaoru Toyama
Takako Shimizu
Manabu Kato
Tomoko Ishizuka
Kazutaka Yoshihara
Hidetoshi Furuie
Yasuhiro Nishikawa
Takafumi Nakatsu
Yutaro Maekawa
Akiko Watanabe
Published In
Adv Ther
Clin Pharmacol Drug Dev
J Clin Pharmacol
Biol Pharm Bull
Antimicrob Agents Chemother
Affiliations
Soon will be listed here.
Recent Articles
1.
Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects
Tachibana M, Matsuki S, Maekawa Y, Kuroda K, Shimizu T, Tsutsumi J, et al.
Clin Transl Sci . 2023 Sep; 16(11):2153-2162. PMID: 37705321
Valemetostat tosylate (valemetostat) is an oral, potent, dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1 under investigation for the treatment of cancer, including non-Hodgkin's lymphomas and solid...
2.
Population pharmacokinetics of esaxerenone, a novel non-steroidal mineralocorticoid receptor blocker, in patients with essential hypertension, patients with diabetic nephropathy, and healthy volunteers
Yoshihara K, Fukae M, Kastrissios H, Wada R, Shimizu T, Ishizuka H
Drug Metab Pharmacokinet . 2023 Sep; 52:100516. PMID: 37690271
Objectives: Esaxerenone is a novel, non-steroidal mineralocorticoid receptor (MR) blocker with improved selectivity and affinity for MR. The objectives of this study were to model the population pharmacokinetics of esaxerenone...
3.
DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study
Toyama K, Eto T, Takazawa K, Shimizu S, Nakayama T, Furihata K, et al.
Vaccine . 2023 Aug; 41(38):5525-5534. PMID: 37586958
Background: DS-5670a is a vaccine candidate for coronavirus disease 2019 (COVID-19) harnessing a novel modality composed of messenger ribonucleic acid (mRNA) encoding the receptor-binding domain (RBD) from the spike protein...
4.
Safety, Tolerability, and Pharmacokinetics of Valemetostat Tablets and the Effect of Food on Valemetostat Pharmacokinetics in Healthy Subjects: Two Phase 1 Studies
Tachibana M, Matsuki S, Toyama K, Maekawa Y, Fukae M, Shimizu T, et al.
Clin Pharmacol Drug Dev . 2023 Aug; 13(1):77-86. PMID: 37565616
Valemetostat is an oral, selective inhibitor of enhancer of zeste homolog-2 (EZH2) and EZH1. In a first-in-human phase-1 trial, valemetostat capsules were well tolerated and clinically active in patients with...
5.
Pharmacokinetics and Bioequivalence of Mirogabalin Orally Disintegrating Tablets and Conventional Tablets in Healthy Japanese Participants
Toyama K, Eto T, Suzuki K, Shinohara S, Yoshiba S, Yoshihara K, et al.
Clin Pharmacol Drug Dev . 2023 Jun; 12(10):985-990. PMID: 37312273
This single-center, randomized, open-label, single-dose, 2-group, 2-stage crossover trial evaluated the bioequivalence of 15 mg of mirogabalin as orally disintegrating tablets (ODTs) with conventional mirogabalin tablets in healthy Japanese men....
6.
Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study
Li Y, Toyama K, Nakatsu T, Ishizuka H, Wu H, Cao G, et al.
Adv Ther . 2023 Feb; 40(4):1628-1643. PMID: 36790683
Introduction: Mirogabalin is a treatment option for patients with neuropathic pain; however, safety, tolerability, and pharmacokinetics (PK) data specifically for Chinese individuals are limited to a single-dose study. We aimed...
7.
Steady-State Pharmacokinetics of Intravenous Hydromorphone in Japanese Patients With Renal Impairment and Cancer Pain
Nakatani T, Shiosakai K, Hashimoto T, Shionoya M, Akasaka T, Toyama K, et al.
J Palliat Med . 2022 Dec; 26(6):768-775. PMID: 36579915
The opioid analgesic hydromorphone has a low renal excretion ratio; however, exposure after oral administration is several times higher in those with moderate or severe renal impairment. We evaluated the...
8.
Bioequivalence of Esaxerenone Conventional Tablet and Orally Disintegrating Tablet: Two Single-Dose Crossover Studies in Healthy Japanese Men
Kurata A, Eto T, Tsutsumi J, Igawa Y, Nishikawa Y, Ishizuka H
Clin Pharmacol Drug Dev . 2022 Mar; 11(8):957-965. PMID: 35315257
We assessed the bioequivalence of a single dose of 5-mg of esaxerenone administered as an orally disintegrating tablet (ODT) with the conventional oral tablet in healthy Japanese men. This single-center,...
9.
Correction to: Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment
Watanabe A, Ishizuka T, Yamada M, Igawa Y, Shimizu T, Ishizuka H
Eur J Clin Pharmacol . 2021 Sep; 78(1):75. PMID: 34494163
No abstract available.
10.
Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment
Watanabe A, Ishizuka T, Yamada M, Igawa Y, Shimizu T, Ishizuka H
Eur J Clin Pharmacol . 2021 Aug; 78(1):65-73. PMID: 34415382
Purpose: Esaxerenone is a novel, oral, nonsteroidal treatment for hypertension. Physiologically based pharmacokinetic (PBPK) modelling was performed to predict the drug-drug interaction (DDI) effect of cytochrome P450 (CYP)3A modulators on...